摘要
Abstract
Objective To investigate the clinical effect of moxifloxacin on the early and intensive treatment of tuberculous pleurisy.Methods 88 cases of patients with tuberculous pleurisy from the department of infectious disease in a people’s hospital of Bijie city, were randomly divided into two groups: observation group (n=44) and control group (n=44). The patients in control group were treated by conventional oral anti-TB drugs, such as isoniazid, rifampicin, pyrazinamide, ethambutol, etc. and pleural puncture fluid therapy, while those in the observation group were given early and intensive treatment of moxifloxacin in two weeks, which was based on the conventional treatment. The clinical symptoms, adverse drug reactions, the absorption of pleural effusion, reduce pleural adhesion and hypertrophy were observed and compared between the two groups.Results All patients were followed up for 1-6 months. There was a total of 38 cases of complete absorption in the observation group, the mean absorption time of pleural effusion was (19.35±2.16) d, and those in the control group was 26 cases and (26.17±3.08) d, respectively, and there was a significant difference between two groups (t=3.245,P=0.037) . The incidence of pleural thickening and adhesion in observation group (n=3) was lower than that in the control group (n=11), and the difference was statistically significant (χ2=6.453,P=0.011). 40 cases in the observation group with effective clinical treatment outcome, which was higher than 33 cases in the control group, the difference was not statistically significant. 8 cases in observation groups with adverse drug reaction, and 7 cases in the control group, the difference was not statistically significant.Conclusions Early and intensive treatment with moxifloxacin on tuberculous pleurisy can improve the early absorption of pleural effusion and reduce pleural adhesion and hypertrophy, and do not obviously increase adverse drug reaction.关键词
莫西沙星/肺结核/胸膜炎/一线抗结核药物Key words
moxifloxacin/tuberculous/exudative pleurisy/first-line anti-TB drugs分类
医药卫生
